Yihong Zhang
机构:Xihua University, Donghua University, Yantai University, Hunan University of Science and Engineering, University of Manchester, Southwest Medical University, Beijing Academy of Artificial Intelligence, Zhongda Hospital Southeast University, Nippon Paint (Japan), Second Affiliated Hospital of Nanjing Medical University, Tianjin Beichen Hospital, Beijing University of Civil Engineering and Architecture, Zhejiang University, Southeast University, Beijing Sport University, Nanjing University · ORCID:0000-0002-6432-3840
发表论文 343 篇 · 总被引 7831 次 · h-index 52
代表论文
- Microenvironmental modulation breaks intrinsic pH limitations of nanozymes to boost their activities (2024 · Nature Communications · 被引 106)
- Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation (2025 · Signal Transduction and Targeted Therapy · 被引 20)
- Discovery of Pyrrolopyrazine Carboxamide Derivatives as Potent and Selective FGFR2/3 Inhibitors that Overcome Mutant Resistance (2025 · Journal of Medicinal Chemistry · 被引 15)
- Design, Synthesis, and Biological Evaluation of Novel Orally Available Covalent CDK12/13 Dual Inhibitors for the Treatment of Tumors (2025 · Journal of Medicinal Chemistry · 被引 13)
- Copper depletion-induced tumor cuproptosis (2024 · Chemical Science · 被引 13)
- Discovery of a Novel Macrocyclic Noncovalent CDK7 Inhibitor for Cancer Therapy (2024 · Journal of Medicinal Chemistry · 被引 11)